Board summary
Key figures
48,532
Registered population
53.5% aged 18–64
29.0%
Aged 65+
ICB 21.9% · England 17.9%
3.6%
Ethnic minority (non-White)
1.2% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
9,495
Hypertension register
+6.84% in 3 yrs · England +5.60%
385
SMI register
30.3% of Horsham's
868
COPD register
Reviews +3.04% in 3 yrs
Forecast to 2030
11,178
Hypertension patients, 2030
+1,683 on today
73.1%
QRISK ≥20% on statins, 2030
+5.22pp over 3 yrs
7.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail England.
Only 58.6% had a review (Horsham 62.4%, ICB 62.5%, England 65.7%), leaving about 1,400 of 3,494 patients unreviewed; this may reflect recall gaps.
High-risk lipid therapy below England.
Lipid therapy in QRISK ≥ 20% is 61.1% (England 63.6%), alongside lags in CKD (64.7% vs 70.3%) and diabetes with CVD (79.7% vs 84.4%).
Hypertension control improved faster than England.
Treatment to target rose +14.0% from 2023 to 2025 (England +3.6%), reaching 71.5% (England 70.3%), with 91.8% having a recent blood pressure reading.
Population, age and ethnicity
Patients aged 65+ make up 29.0% of the list, above England's 17.9%
Chanctonbury PCN has 48,532 registered patients with an older demographic: 29.0% are aged 65+ (14,096 patients), exceeding Horsham (23.7%), NHS Sussex Integrated Care Board (21.9%), and England (17.9%). Patients aged 18–64 represent 53.5% (Horsham 57.6%, ICB 60.5%, England 62.7%) and those aged 0–17 comprise 17.4% (Horsham 18.7%, ICB 17.7%, England 19.6%). Census resident estimates, which describe local residents rather than registered patients, show 96.4% White ethnicity (Horsham 93.6%, ICB 91.0%, England 81.1%), leaving a 3.6% ethnic minority share, with 1.2% Asian and 0.3% Gypsy or Irish Traveller residents. Projected population growth to 2030 is 3.2% (unverified method).
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Horsham local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Horsham LA) | 2,154 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.4% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 63.7% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Horsham LA) | 909 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Horsham LA) | 10.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 7.7 with 0.0% Core20 patients across all four practices
The PCN average IMD decile is 7.7 (Horsham 8.2, NHS Sussex Integrated Care Board 6.1, England 5.5). Across all four practices, 0.0% of registered patients are in the Core20 cohort (Horsham 0.0%, NHS Sussex Integrated Care Board 9.2%, England 21.0%), representing an estimated 0 Core20 patients. Practice deciles range from 7.2 at Henfield Medical Centre and 7.3 at Billingshurst Surgery to 8.0 at Steyning Health Centre and Glebe Surgery. Zero Core20 concentration shifts inequality focus toward clinical inclusion cohorts rather than area deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
385
SMI register
0.78% recorded prevalence
265
Learning disability register
0.54% recorded prevalence
14
Care homes, 519 beds
In the PCN catchment
8.0%
Provide unpaid care
Horsham, Census 2021
Recorded inclusion health registers capture 265 patients with a learning disability (0.5%, England 0.6%) and 385 with severe mental illness (0.8%, England 1.0%), alongside 14 catchment care homes with 519 beds. With recorded severe mental illness and learning disability prevalence trailing England rates, structured annual physical health checks and coordinated care home reviews are the primary inclusion workload to prioritise.
Severe mental illness: physical health checks
SMI checks reached 84.0% for blood pressure and 84.4% for BMI (England 83.4% and 82.1%). Smoking cessation offers for indicated conditions reached 88.7% (England 94.2%), trailing at Billingshurst Surgery at 71.4%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,495
Hypertension register
+6.84%
Register growth, 3 yrs
Horsham +4.65% · England +5.60%
+7.21pp
BP control, under 80
≤140/90 · +4.19pp aged 80+
+1,683
More patients by 2030
Forecast 11,178 (22.05%)
Hypertension case-finding and control
Hypertension prevalence is 19.3% (9,495 patients), above Horsham (16.8%), NHS Sussex Integrated Care Board (16.3%), and England (15.2%). Recent blood pressure monitoring reached 91.8%, exceeding England (90.0%) and the ICB (90.2%), while trailing Horsham (92.0%). Patients treated to target rose +14.0% over 2023 to 2025 (England +3.6%) to 71.5%, above England (70.3%) but below Horsham (73.8%). For patients aged under 80, control to <= 140/90 mmHg is 68.8%, trailing Horsham (71.5%) despite exceeding England (67.8%). Trailing borough-level blood pressure control among patients aged under 80 suggests potential scope to review clinical management and medication titration.
Lipids and statins
Lipid-lowering therapy trails England across high-risk groups: QRISK ≥ 20% reaches 61.1% (England 63.6%), CKD is 64.7% (England 70.3%), and diabetes with CVD is 79.7% (England 84.4%). Lower treatment rates compared to England across high-risk groups suggest scope to review clinical recall and therapy initiation.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 104,322 | £2.30 | £2.42 | £1.86 | £239,941 |
| Cardiovascular (all), 2025 | 129,645 | £3.16 | £3.32 | £3.33 | £409,678 |
In 2026, lipid-regulating drugs totalled 104,322 items at £2.30 per item, below Horsham (£2.64) and NHS Sussex Integrated Care Board (£2.42) but above England (£1.86). The PCN spent £45,902 more than at England's unit cost and £12,519 less than at the ICB's unit cost. Unit costs could reflect formulary choices rather than prescribing efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+11.19%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+5.00%
Asthma prevalence, PCN 3-yr % change
The asthma register includes 3,494 patients (7.5% prevalence, England 6.6%), but 12-month reviews reached 58.6%, trailing Horsham (62.4%), NHS Sussex Integrated Care Board (62.5%), and England (65.7%), leaving about 1,400 unreviewed patients. Reviews were 38.5% at Billingshurst Surgery and 72.1% at Steyning Health Centre. Recorded COPD prevalence is 1.8% (868 patients), with reviews at 66.9% trailing England (76.4%). Structured clinical recall could help address these unreviewed respiratory cohorts.
Cancer register and children's immunisation
Cancer prevalence is 6.0% (2,930 patients, England 3.8%). In Q1 2025/26, 12- and 24-month immunisations exceeded the 95.0% target (6-in-1 at 96.5%, MMR1 at 96.1%). At age 5, coverage was below the 95.0% target for MMR2 (88.0%) and 4-in-1 (87.0%, denominator 108), with same-cohort MMR dose differences of 8 pp at Steyning Health Centre and 5.6 pp at Glebe Surgery.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of cancers with a known stage in NHS Sussex ICB were diagnosed at stage 1 or 2 (4,799 of 8,209), above England (55.3%) but below the 75.0% national ambition by 2028 by 16.5 pp. Stage was known for 64.3% of 12,766 registered cancers (England 67.0%), requiring about 1,360 extra early diagnoses annually; these ICB figures reflect wider system staging rather than PCN performance, and specific cancer sites carry small-number limits. In CHANCTONBURY PCN, cancer prevalence is 6.0% (2,930 patients) and cervical screening is 76.0% (England 66.8%), but three-year register growth of +8.0% trails England (+9.0%), which clinical audit can review.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day cancer referral to treatment standard, below the 85.0% standard by 19.8 pp, trailing Surrey and Sussex Healthcare NHS Trust (70.0%), Royal Surrey NHS Foundation Trust (84.5%), NHS Surrey and Sussex Integrated Care Board (71.5%), and England (71.2%). The trust reached 74.0% for the 28-day faster diagnosis standard (standard 75.0%) and 76.8% for 31-day treatment (standard 96.0%). For diagnostics, 39.3% waited 6+ weeks for colonoscopy (England 30.8%). Secondary care delays could impede prompt diagnosis and management for referred patients.
| Pathways within standard (%) | Sussex | Surrey and Sussex Healthcare | Royal Surrey | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 77.74 | 82.62 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 96.20 | 96.43 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 69.97 | 84.48 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | Surrey and Sussex Healthcare | Royal Surrey | England |
|---|---|---|---|---|
| MRI | 5.62 | 27.53 | 0.00 | 21.40 |
| CT | 8.57 | 18.49 | 0.15 | 9.92 |
| Echocardiography | 0.39 | 43.78 | 1.55 | 28.48 |
| Colonoscopy | 39.35 | 15.11 | 0.00 | 30.83 |
| Gastroscopy | 20.02 | 21.06 | 0.00 | 29.02 |
| All 15 DM01 tests | 12.95 | 28.50 | 8.82 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In June 2026 (provisional), 72.7% of community service contacts among Horsham residents were with adults aged 65 and over (56,740 of 78,050 contacts). These figures describe wider-system activity across the local authority district rather than PCN-level provision, reflecting non-acute care delivery where provider-level breakdowns are not captured.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF vaccination achievement spans 47.6 pp, from 39.1% at Billingshurst Surgery to 86.6% at Glebe Surgery (Henfield Medical Centre 48.7%, Steyning Health Centre 75.0%, England 55.2%). Clinical-domain achievement reaches 96.7% at Glebe Surgery, 100.0% at Henfield Medical Centre, and 100.0% at Steyning Health Centre (England 97.1%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Glebe Surgery | 118 | 0.0 | 74.9% | 83.1% | 91.6% |
| Steyning | 104 | 0.0 | 76.4% | 74.9% | 86.5% |
| Billingshurst | 118 | 0.0 | 45.9% | 78.4% | 81.1% |
| Henfield | 102 | 0.0 | 48.1% | 78.3% | 77.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Seven measures trail England over three years despite hypertension treatment rising +14.0%
Across three-year trend measures, seven trail England. Relative growth lagged in breast screening (+5.4% vs England +8.4%) and statin therapy for diabetes without CVD (+0.3% vs England +2.1%). Conversely, substantial process gains occurred: heart failure reviews rose +17.4% (England +8.7%) and hypertension treated to target increased +14.0% (England +3.6%). Smoking cessation support offers expanded by +14.6 pp (England +0.1 pp), though current coverage of 88.7% remains below England (94.2%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Breast screening (53-70)
Diabetes statin (no CVD)
Dementia register
Depression register
Cancer register
Smoking support (SMI)
Hypertension treated to target
Heart failure reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Horsham | Asset | PCN | Horsham |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (519 beds) | n/a | Schools (catchment) | 45 | n/a |
| Children's centres | 2 | 9 | Places of worship | 63 | 93 |
| Libraries | 4 | 7 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 2 | 7 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | 1 | 2 | Primary schools (LA maintained) | 19 | 37 |
| Primary academies | 3 | 6 | Special schools | 2 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Standardise annual asthma review recall
Asthma reviews reach 58.6% (below Horsham 62.4%, NHS Sussex Integrated Care Board 62.5%, England 65.7%), leaving 1,448 patients (about 1,400) of 3,494 unreviewed. For discussion: the PCN could run structured asthma recall using a single clinical template and flexible appointments, starting at the lowest-scoring practice. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
High-risk lipid therapy and formulary review
Lipid therapy trails England in QRISK ≥ 20% (61.1% vs 63.6%), CKD (64.7% vs 70.3%), and diabetes with CVD (79.7% vs 84.4%); 104,322 items at £2.30 cost £45,902 more than at England's £1.86 unit cost. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 108), age-5 coverage trails the 95.0% target by 7 pp for MMR2 (88.0%) and 8 pp for 4-in-1 (87.0%), with an 8 pp MMR1-to-MMR2 drop at Steyning Health Centre. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Anticipatory care and frailty review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Condition smoking cessation recall (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension control optimisation (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register review (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Telephone access and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Standardise annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · High-risk lipid therapy and formulary review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
| Option 3 · Pre-school booster and MMR2 recall (p12) | MMR dose 1 coverage at 24 months · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
